Abstract:
:The response to stress triggers transcriptional activation of genes involved in cell survival and/or cell death. Thus, the monitoring of gene expression levels in large gene sets or whole genomes in response to various agents (toxicogenomics) has been proposed as a tool for investigating mechanisms of toxicity. Although standard in vitro genetic toxicity testing provides relatively simple and accurate hazard detection, interpretation of positive findings, i.e., in vitro chromosome aberrations, in terms of relevant risk to humans is difficult, due to the limited insight into the underlying mechanisms. Therefore, the development of experimental approaches capable of differentiating a wide range of genotoxic mechanisms is expected to significantly improve risk assessment. The goal of this review is to summarize current developments in toxicogenomic analysis of genotoxic stress, and to provide a perspective on the application of gene expression profile analysis in genetic toxicology.
journal_name
Pharmacogenomicsjournal_title
Pharmacogenomicsauthors
Aubrecht J,Caba Edoi
10.1517/14622416.6.4.419keywords:
subject
Has Abstractpub_date
2005-06-01 00:00:00pages
419-28issue
4eissn
1462-2416issn
1744-8042journal_volume
6pub_type
杂志文章,评审相关文献
PHARMACOGENOMICS文献大全abstract:AIM:A population pharmacokinetic (PPK) analysis was conducted to describe the influence of GSTA1 polymorphisms on intravenous busulfan in adults undergoing allogeneic hematopoietic stem cell transplantation. PATIENTS & METHODS:A PPK model was developed from 36 patients by a one-compartment model with first-order elimi...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs.15.98
更新日期:2015-01-01 00:00:00
abstract::The aim of this work was to determine the VKORC1 haplotype profile in healthy Hungarian and Roma population samples, and to compare our data with other selected populations. Using haplotype tagging SNPs (G-1639A, G9041A and C6009T), we characterized Hungarian (n = 510) and Roma (n = 451) population samples with regard...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs.09.46
更新日期:2009-06-01 00:00:00
abstract::Founded as a spin-off from the University of Vienna in 1999, VBC-GENOMICS Bioscience Research GmbH (LLC) has rapidly gained a strong position within the Austrian biotech scene, based on its success as a service provider in oligonucleotide synthesis and custom sequencing. In research, the company has focused on the dev...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.1517/14622416.5.4.439
更新日期:2004-06-01 00:00:00
abstract::The emergence of antibiotic resistance and multi-drug resistance in bacterial pathogens underscores the need for the development of novel classes of antibiotics. The availability of complete genome sequence data from many important human pathogens provides a wealth of fundamental information. This allows us to define ...
journal_title:Pharmacogenomics
pub_type: 杂志文章,评审
doi:10.1517/14622416.3.3.315
更新日期:2002-05-01 00:00:00
abstract:AIMS:Individuals with both diabetes mellitus (DM) and the Haptoglobin (Hp) 2-2 genotype are at increased risk of cardiovascular disease. As the antioxidant function of the Hp 2-2 protein is impaired, we sought to test the pharmacogenomic hypothesis that antioxidant vitamin E supplementation would provide cardiovascular...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs.10.17
更新日期:2010-05-01 00:00:00
abstract::Cambridge Healthtech Institute's Third Annual Conference on Lab-on-a-Chip and Microarray technology covered the latest advances in this technology and applications in life sciences. Highlights of the meetings are reported briefly with emphasis on applications in genomics, drug discovery and molecular diagnostics. Ther...
journal_title:Pharmacogenomics
pub_type:
doi:10.1517/14622416.2.1.73
更新日期:2001-02-01 00:00:00
abstract::Recent studies have suggested an association between mutations in the IL-36RN gene and the onset of pustular generalized. In the literature, only one case of acute generalized exanthematous pustulosis (AGEP) induced by codeine in a patient with IL36RN mutation has been reported. Herein, we reported an unusual case of ...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs-2017-0200
更新日期:2018-07-01 00:00:00
abstract:INTRODUCTION:Marked lowering of low-density-lipoprotein cholesterol (LDL-C) levels (< or =50%) with intensive statin therapy is associated with major reduction in cardiovascular risk, but is limited by a potential increase in adverse effects, thereby justifying optimization of LDL-C reduction with minimal risk. The org...
journal_title:Pharmacogenomics
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.2217/14622416.9.9.1217
更新日期:2008-09-01 00:00:00
abstract:AIM:Pharmacogenomics could play a role in improving patient care, reducing adverse drug reactions and overall healthcare costs. However, whether it is utilized may be determined by how it is perceived by healthcare professionals, including pharmacists. METHODS:A cross-sectional web-based survey evaluated psychiatric p...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs.15.22
更新日期:2015-01-01 00:00:00
abstract:AIM:To investigate the role of genetic polymorphisms in glutamatergic and GABAergic genes and their interactions with environmental stressors in antidepressant response. METHODS:A set of 114 SNPs of 34 glutamatergic and GABAergic genes, mainly in promoter and coding regions, were genotyped in 281 Chinese Han major dep...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs.13.1
更新日期:2013-02-01 00:00:00
abstract:AIM:We investigated 16 polymorphisms from three genes, dopamine receptor D2 (DRD2), catechol-O-methyl transferase (COMT) and brain derived neurotrophic factor (BDNF), which are involved in the dopaminergic pathways, and have been reported to be associated with susceptibility to schizophrenia and response to antipsychot...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/14622416.10.2.277
更新日期:2009-02-01 00:00:00
abstract:BACKGROUND:Patients with mild-to-moderate essential hypertension in the HOMED-BP trial were randomly allocated to first-line treatment with a calcium channel blocker (CCB), angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB). METHODS:We recruited 265 (93 for CCB, 71 for ACEI and 101...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs.13.161
更新日期:2013-11-01 00:00:00
abstract::Human cytochrome P450 (CYP)3A is a major P450 enzyme found in the liver and gastrointestinal tract. It plays an important role in the metabolism of a wide variety of drugs, some endogenous steroids and harmful environmental contaminants. It has been shown that CYP3A alleles encoding enzymes with little or no activity ...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/14622416.6.7.731
更新日期:2005-10-01 00:00:00
abstract:AIM:We examined whether HLA-DRB1*1501 and four VDR SNPs influence the macrophage response to infection with Mycobacterium tuberculosis (Mtb) via innate immune versus drug treatment or drug delivery mechanisms. MATERIALS & METHODS:Monocyte-derived macrophages from 24 healthy donors were infected with Mtb in vitro. Surv...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs.13.12
更新日期:2013-04-01 00:00:00
abstract::Comprehensive, personalized medication management and pharmacogenetic testing are important existing opportunities to reduce adverse medication events and improve overall healthcare outcomes. A primary barrier to the adoption of personalized pharmacology is the inadequacy of existing patient records, drug interaction ...
journal_title:Pharmacogenomics
pub_type: 杂志文章,评审
doi:10.2217/14622416.9.4.469
更新日期:2008-04-01 00:00:00
abstract::CYP2D6*84 was first described in a Black South African subject, however, its function remains unknown. Astrolabe, a probabilistic scoring tool developed in our laboratory to call genotypes from whole genome sequence, identified CYP2D6*84 in a trio. The father presented with intermediate metabolism when challenged with...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs-2016-0192
更新日期:2017-04-01 00:00:00
abstract::For the last 40 years, 5-fluorouracil (5-FU) has remained the treatment of choice in both the adjuvant and advanced treatment of colorectal cancer (CRC). However, 5-FU monotherapy produces response rates of only 10-20% in the advanced setting. 5-FU has been combined with newer agents, such as oxaliplatin and irinoteca...
journal_title:Pharmacogenomics
pub_type: 杂志文章,评审
doi:10.2217/14622416.6.6.603
更新日期:2005-09-01 00:00:00
abstract::HIV-infected individuals may have accelerated atherogenesis and an increased risk for premature coronary artery disease. Dyslipidemia represents a key pro-atherogenic mechanism. In HIV-infected patients, dyslipidemia is typically attributed to the adverse effects of antiretroviral therapy. Nine recent genome-wide asso...
journal_title:Pharmacogenomics
pub_type: 杂志文章,评审
doi:10.2217/pgs.10.35
更新日期:2010-04-01 00:00:00
abstract:AIM:Based on previous pharmacogenetic findings, we investigated the possible association between SULT4A1-1 haplotype and antipsychotic treatment response. MATERIALS & METHODS:Using Mixed Model Repeated Measures, we tested the relationship between SULT4A1-1 status (+carrier, -noncarrier) and clinical improvement (in Po...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs.14.105
更新日期:2014-01-01 00:00:00
abstract::Pharmacogenomics seeks to understand the genetic basis of interindividual differences in drug disposition and effects. Differential drug response is likely to most often be a complex trait, in which multiple genes contribute with varying strengths to the therapeutic phenotype. Due to technical and economic limitations...
journal_title:Pharmacogenomics
pub_type: 杂志文章,评审
doi:10.1517/14622416.3.6.781
更新日期:2002-11-01 00:00:00
abstract::Chronic obstructive pulmonary disease (COPD) is influenced by genetic and environmental factors. A large number of candidate gene-association studies and genome-wide linkage scans have been conducted to elucidate the genetic architecture underlying this disease. The compilation of these studies clearly revealed the co...
journal_title:Pharmacogenomics
pub_type: 杂志文章,评审
doi:10.2217/pgs.09.10
更新日期:2009-04-01 00:00:00
abstract::This narrative review describes implementation, current status and perspectives of a pharmacogenomic (PGx) program at the Brazilian National Cancer Institute (INCA), targeting the cancer chemotherapeutic drugs - fluoropyrimidines, irinotecan and thiopurines. This initiative, designed as a research project, was support...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs-2020-0016
更新日期:2020-06-01 00:00:00
abstract:INTRODUCTION:Most cancer pharmacogenetic studies use germline DNA, as tumor tissue is often inaccessible in the advanced disease setting. However, this relies on the assumption that germline DNA is representative of the tumor genotype. To date, there has been little attention paid to defining the relationship between t...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/14622416.6.8.873
更新日期:2005-12-01 00:00:00
abstract::The multi-drug resistant transporter MDR1/P-glycoprotein, the gene product of MDR1, is a glycosylated membrane protein of 170 kDa, belonging to the ATP-binding cassette (ABC) superfamily of membrane transporters. MDR1 was originally isolated from resistant tumor cells as part of the mechanism of multi-drug resistance,...
journal_title:Pharmacogenomics
pub_type: 杂志文章,评审
doi:10.1517/phgs.4.4.397.22747
更新日期:2003-07-01 00:00:00
abstract::Asthma is one of the most common respiratory diseases, where inhalation and exhalation are obstructed due to narrowing of the airways by broncho-constriction or by inflammation. Among all the available anti-asthma therapies, beta2-agonists are the most effective bronchodilators available, and give rapid relief of asth...
journal_title:Pharmacogenomics
pub_type: 杂志文章,评审
doi:10.2217/14622416.7.6.919
更新日期:2006-09-01 00:00:00
abstract::The 4th US FDA/Industry workshop, in a series on Pharmacogenomics, was on 'Biomarkers and Pharmacogenomics in Drug Development and Regulatory Decision Making' and was held on December 10-12, 2007 in Bethesda, MD, USA, with clear objectives to continue the dialogue that began in 2002 for enabling the use of biomarkers ...
journal_title:Pharmacogenomics
pub_type:
doi:10.2217/14622416.10.1.111
更新日期:2009-01-01 00:00:00
abstract:AIM:Our objective was to describe the association between voriconazole concentrations and CYP2C19 diplotypes in pediatric cancer patients, including children homozygous for the CYP2C19*17 gain-of-function allele. MATERIALS & METHODS:A linear mixed effect model compared voriconazole dose-corrected trough concentrations...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs.14.53
更新日期:2014-06-01 00:00:00
abstract::Genetic variation in the beta 2-adrenoceptor and its associated proteins is common and therefore potentially relevant to the clinician. Several functional SNPs have been described but in vitro studies have yielded inconsistent results. Confounding due to the variable presence of other polymorphic alleles may be the ex...
journal_title:Pharmacogenomics
pub_type: 杂志文章,评审
doi:10.1517/14622416.3.2.173
更新日期:2002-03-01 00:00:00
abstract::The etiology of statin intolerance is hypothesized to be due to genetic variants that impact statin disposition and clearance. We sought to determine whether genetic variants were associated to statin intolerance. The studied cohort consisted of hyperlipidemic participants (n = 90) clinically diagnosed with statin int...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs-2017-0146
更新日期:2018-01-01 00:00:00
abstract::Aim: We investigated if DEPTOR polymorphisms influence metabolic parameters and risk for vascular complications in Type 2 diabetes (T2D) patients. Methods: T2D patients were genotyped for DEPTOR rs7840156, rs2271900 and rs4871827. We built low homology model of DEPTOR to check the position of two investigated substitu...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs-2019-0058
更新日期:2019-08-01 00:00:00